Details
Title
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ
Author
Ding, Lina 1 ; Su, Ying 2 ; Fassl, Anne 3 ; Hinohara, Kunihiko 4 ; Qiu, Xintao 5 ; Harper, Nicholas W 6 ; Sung Jin Huh 7 ; Noga Bloushtain-Qimron 8 ; Jovanović, Bojana 1 ; Muhammad Ekram 9 ; Zi, Xiaoyuan 10
; Hines, William C 11 ; Alečković, Maša 1
; Gil del Alcazar, Carlos 1 ; Caulfield, Ryan J 12 ; Bonal, Dennis M 12
; Quang-De Nguyen 12 ; Merino, Vanessa F 13 ; Choudhury, Sibgat 14 ; Ethington, Gabrielle 15 ; Panos, Laura 15 ; Grant, Michael 15 ; Herlihy, William 15 ; Au, Alfred 16 ; Rosson, Gedge D 13 ; Argani, Pedram 13 ; Richardson, Andrea L 17 ; Dillon, Deborah 18 ; Allred, D Craig 19 ; Babski, Kirsten 20 ; Hui Kim, Elizabeth Min 21 ; McDonnell, Charles H, III 20 ; Wagner, Jon 20 ; Rowberry, Ron 20 ; Bobolis, Kristie 20 ; Kleer, Celina G 22 ; E Shelley Hwang 23 ; Blum, Joanne L 15 ; Cristea, Simona 24 ; Sicinski, Piotr 3
; Fan, Rong 25
; Long, Henry W 26
; Sukumar, Saraswati 13 ; Park, So Yeon 27 ; Garber, Judy E 1 ; Bissell, Mina 28
; Yao, Jun 29 ; Polyak, Kornelia 30
1 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
2 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Deciphera Pharmaceuticals, Waltham, MA, USA
3 Department of Cancer Biology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
4 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Nagoya University Graduate School of Medicine, Nagoya, Japan
5 Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA
6 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA
7 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; ImmunoGen, Inc, Waltham, MA, USA
8 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; EMEA Site Intelligence and Activation, Tel Aviv, Israel
9 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; WuXi NextCODE, Cambridge, MA, USA
10 Department of Biomedical Engineering, Yale University, New Haven, CT, USA; Second Military Medical University, Shanghai, P.R. China
11 Lawrence Berkeley National Laboratory, Berkeley, CA, USA; University of New Mexico School of Medicine, Albuquerque, NM, USA
12 Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA
13 Johns Hopkins University School of Medicine, Baltimore, MD, USA
14 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Metamark Genetics Inc, Worcester, MA, USA
15 Baylor-Charles A. Sammons Cancer Center, Dallas, TX, USA
16 University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
17 Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA; Department of Pathology, Harvard Medical School, Boston, MA, USA; Johns Hopkins Medical Institutions, Baltimore, MD, USA
18 Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA; Department of Pathology, Harvard Medical School, Boston, MA, USA
19 Department of Pathology, Washington University School of Medicine, St. Louis, MO, USA
20 Sutter Roseville Medical Center, Roseville, CA, USA
21 Sutter Roseville Medical Center, Roseville, CA, USA; Cancer Treatment Centers of America, Atlanta, GA, USA
22 Department of Pathology, University of Michigan, Ann Arbor, MI, USA
23 University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Duke University, Durham, NC, USA
24 Department of Data Science, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Biostatistics, Harvard T. H. Chan School of Public Health Boston, Boston, MA, USA; Department of Stem Cell and Regenerative Biology, Harvard University Cambridge, Cambridge, MA, USA
25 Department of Biomedical Engineering, Yale University, New Haven, CT, USA
26 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA
27 Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
28 Lawrence Berkeley National Laboratory, Berkeley, CA, USA
29 MD Anderson Cancer Center, Houston, TX, USA
30 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Stem Cell Institute, Cambridge, MA, USA
; Hines, William C 11 ; Alečković, Maša 1
; Gil del Alcazar, Carlos 1 ; Caulfield, Ryan J 12 ; Bonal, Dennis M 12
; Quang-De Nguyen 12 ; Merino, Vanessa F 13 ; Choudhury, Sibgat 14 ; Ethington, Gabrielle 15 ; Panos, Laura 15 ; Grant, Michael 15 ; Herlihy, William 15 ; Au, Alfred 16 ; Rosson, Gedge D 13 ; Argani, Pedram 13 ; Richardson, Andrea L 17 ; Dillon, Deborah 18 ; Allred, D Craig 19 ; Babski, Kirsten 20 ; Hui Kim, Elizabeth Min 21 ; McDonnell, Charles H, III 20 ; Wagner, Jon 20 ; Rowberry, Ron 20 ; Bobolis, Kristie 20 ; Kleer, Celina G 22 ; E Shelley Hwang 23 ; Blum, Joanne L 15 ; Cristea, Simona 24 ; Sicinski, Piotr 3
; Fan, Rong 25
; Long, Henry W 26
; Sukumar, Saraswati 13 ; Park, So Yeon 27 ; Garber, Judy E 1 ; Bissell, Mina 28
; Yao, Jun 29 ; Polyak, Kornelia 30
1 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
2 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Deciphera Pharmaceuticals, Waltham, MA, USA
3 Department of Cancer Biology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
4 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Nagoya University Graduate School of Medicine, Nagoya, Japan
5 Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA
6 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA
7 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; ImmunoGen, Inc, Waltham, MA, USA
8 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; EMEA Site Intelligence and Activation, Tel Aviv, Israel
9 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; WuXi NextCODE, Cambridge, MA, USA
10 Department of Biomedical Engineering, Yale University, New Haven, CT, USA; Second Military Medical University, Shanghai, P.R. China
11 Lawrence Berkeley National Laboratory, Berkeley, CA, USA; University of New Mexico School of Medicine, Albuquerque, NM, USA
12 Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA
13 Johns Hopkins University School of Medicine, Baltimore, MD, USA
14 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Metamark Genetics Inc, Worcester, MA, USA
15 Baylor-Charles A. Sammons Cancer Center, Dallas, TX, USA
16 University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
17 Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA; Department of Pathology, Harvard Medical School, Boston, MA, USA; Johns Hopkins Medical Institutions, Baltimore, MD, USA
18 Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA; Department of Pathology, Harvard Medical School, Boston, MA, USA
19 Department of Pathology, Washington University School of Medicine, St. Louis, MO, USA
20 Sutter Roseville Medical Center, Roseville, CA, USA
21 Sutter Roseville Medical Center, Roseville, CA, USA; Cancer Treatment Centers of America, Atlanta, GA, USA
22 Department of Pathology, University of Michigan, Ann Arbor, MI, USA
23 University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Duke University, Durham, NC, USA
24 Department of Data Science, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Biostatistics, Harvard T. H. Chan School of Public Health Boston, Boston, MA, USA; Department of Stem Cell and Regenerative Biology, Harvard University Cambridge, Cambridge, MA, USA
25 Department of Biomedical Engineering, Yale University, New Haven, CT, USA
26 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA
27 Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
28 Lawrence Berkeley National Laboratory, Berkeley, CA, USA
29 MD Anderson Cancer Center, Houston, TX, USA
30 Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Stem Cell Institute, Cambridge, MA, USA
Pages
1-16
Publication year
2019
Publication date
Sep 2019
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2290064700
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.